Farmas USA

Los futuros vienen rojos. Confiemos en que el IBB se los pase por el forro.

Achillion Announces 100% SVR Reported in Janssen's Phase 2a Trial Evaluating Triple Combination of Odalasvir, AL-335, and Simeprevir for Genotype 1 Treatment-Naive HCV
ACHN
• Interim results from Janssen's (NYSE:JNJ) Phase 2a clinical assessing a triple combination therapy for the treatment of HCV showed a 100% cure rate in as little as six weeks. The data will be presented at the European Association for the Study of the Liver Special Conference in Paris, September 23 - 24.
• The aim of the ongoing study is to confirm the required dose and treatment duration for an all-oral combination regimen of odalasvir and AL-335 with or without simeprevir for six or eight weeks in treatment-naive HCV genotype 1 patients.
• The 20 subjects in cohort 1 received a daily dose of the combination of odalasvir (50 mg), AL-335 (400 mg) and simeprevir (100 mg) for eight weeks. All achieved clinical cure 24 weeks after completed therapy (SVR24).
• The 20 patients in cohort 2 received 800 mg of AL-335 every day and 50 mg of odalasvir every other day for eight weeks. The cure rate at 12 weeks post treatment (SVR12) was 90%.
• The 20 subjects in cohort 3 received 800 mg of AL-335 and 75 mg of simeprevir every day and 50 mg of odalasvir every other day for eight weeks. All achieved clinical cure four weeks after the end of therapy (SVR4).
• The 20 subjects in cohort 4 received the same regimen as cohort 3 but for only six weeks. HCV RNA was negative in 90% (n=18/20) and the other two were below the limit of quantitation at the end of treatment.
• The triple combination (odalasvir 25 mg, AL-335 800 mg, simeprevir 75 mg) once daily will now be assessed in a Phase 2b study in 400 patients with chronic HCV 1-6 infection. According to ClinicalTrials.gov, the estimated study completion date is July 2017. The Phase 2a will be expanded to included HCV  -2 and -3 and those with or without compensated cirrhosis.
• AL-335 is a uridine-based nucleoside NS5B polymerase inhibitor being developed by Janssen unit Alios BioPharma. Odalasvir (formerly ACH-3102) is an NS5A inhibitor discovered by Achillion Pharmaceuticals (NASDAQ:ACHN). Simeprevir, a NS3/4A protease inhibitor, is currently marketed by Janssen as Olysio.

‎Kim Jong-un se ha puesto corto.

GILD

President and CEO of Gilead Sciences Inc (GILD) John F Milligan sold 70,000 shares of GILD on 09/06/2016 at an average price of $77.74 a share. The total sale was $5.4 million.

NVAX

Una artículo automático de esos, pero lo dejo para que conste.

Novavax, Inc. breached its 50 day moving average in a Bullish Manner

http://www.capitalcube.com/blog/index.php/novavax-inc-breached-its-50-day-moving-average-in-a-bullish-manner-nvax-us-september-9-2016/

CYAD

Celyad completes the NKR-2 Phase I trial with successful safety follow-up of the fourth dose level

No safety issues or dose limiting toxicity reported.
The trial was a single administration, dose escalation study evaluating the safety and feasibility of NKR-2 T-cell therapy in patients with Acute Myeloid Leukemia or Multiple Myeloma.
Results of the trial are expected to be available in late Q4 2016 -> habría que pasarla a observación. Si no recuerdo mal los Baker andaban dentro.

http://finance.yahoo.com/news/celyad-celyad-completes-nkr-2-050821612.html

ACHN

Pinta un buen largo. 79,90% institucionales. Si acompañara el IBB... ¿Alguien sabe cómo va de pasta?

Edit: Bastardo encantado: triple DAA passes thru ph2, so far behind, can’t even be seen in rear-view mirror. Remember, $GILD has triple DAA son/vel/vox in ph3.

Gráfico de David.

Yo tengo una posición bastante grande desde hace 2 años. J&J se hace cargo de todo el Desarollo de la Hep C desde el Deal y ACHN que ahora tiene mucha pasta, se lla gasta en la plataforma para factor D en Orphan Drug, muy prometedora. Él Deal de J&J compró acciones a $12'50